Studies conducted in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) compared various cassette configurations and informed the final design of TN-201, which incorporates a ...

the company’s gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy (HCM), in Nature Communications. “The extensive body of preclinical data ...

To measure the efficacy of TN-201, a mouse surrogate of TN-201 (mTN-201) was tested against vehicle in a homozygous Mybpc3-deficient murine model that mimics severe disease in humans. Treatment ...

Tenaya Therapeutics (TNYA) announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for ...

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated ...

Tenaya Therapeutics, Inc. announced that it will present new data on its MYBPC3-associated hypertrophic cardiomyopathy (HCM) program at the American College of Cardiology's Annual Scientific ...

Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201SOUTH ...

Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya's Clinical Development Plan to Evaluate TN-201 as a Potential Treatment for Patients with MYBPC3-associated ...

Tenaya Therapeutics reports positive preclinical data for TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy, published in Nature Communications. Tenaya Therapeutics ...